Mereo BioPharma Partners with Sentynl for Alvelestat in AATD-LD — Up to $475M in Milestones Plus Royalties

summarizeSummary

Mereo BioPharma has partnered with Sentynl Therapeutics for alvelestat in AATD-LD, securing an option fee, up to $475 million in total milestones, and double-digit royalties on U.S. sales. Sentynl will fund the Phase 3 program upon option exercise, while Mereo leads development and retains ex-U.S. rights.

check_boxKey Events · M&A and Partnerships · MREO

• Alvelestat Partnership with Sentynl

  Mereo granted Sentynl an exclusive option for U.S. commercial and global manufacturing rights to alvelestat for AATD-LD. Mereo retains rest-of-world commercial rights and leads the global Phase 3 study.

• Up to $475M in Milestones Plus Royalties

  On option exercise, Mereo receives $40M in upfront and R&D payments, up to $435M in regulatory and commercial milestones, and double-digit tiered royalties on U.S. net sales. A non-refundable option fee is paid upfront.

• Phase 3 Funding Secured

  Sentynl will fund the alvelestat Phase 3 development program upon option exercise, removing a major financing overhang. The study could initiate in early 2027.

• Strategic Validation for Micro-Cap Biotech

  The deal with Sentynl, a Zydus subsidiary with rare-disease commercial infrastructure, validates alvelestat's potential and provides non-dilutive capital, critical for a company with a ~$43M market cap.

auto_awesomeAnalysis · MREO · Life Sciences

A transformative partnership has been struck: Mereo BioPharma granted Sentynl Therapeutics an option and license for U.S. commercial and global manufacturing rights to alvelestat, its Phase 3-ready oral therapy for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). The deal brings a non-refundable option fee upfront, and if the option is exercised, $40 million in upfront and R&D payments, up to $435 million in regulatory and commercial milestones, and double-digit tiered royalties on U.S. sales. While Mereo retains rest-of-world commercial rights and will lead the global Phase 3 study, Sentynl commits to funding development upon option exercise. This alliance not only validates alvelestat's promise by securing a dedicated rare-disease partner with commercial infrastructure, but also preserves Mereo's upside outside the U.S. Critically, it addresses a key risk — funding the pivotal Phase 3 program — and extends the company's cash runway, which was already sufficient into mid-2027. For a micro-cap biotech with a market cap around $43 million, a deal offering up to $475 million in total milestones plus royalties is transformative, though the bulk of the value is back-end loaded and contingent on clinical and regulatory success.